Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria. Matsubara D, Takahagi S, Saito R, Kamegashira A, et al. J Dermatol 2021;48:56-63.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Matsubara D, Takahagi S, Saito R, Kamegashira A, et al. Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria. J Dermatol 2021;48:56-63.
PMID: 33029864